Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 845 of 5804
-
Could a weekly shot replace daily growth hormone for kids?
Disease control CompletedA six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis. The primary aim is to demonstrate safety, pharmacokinetics and …
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental gene therapy targets rare immune disorder
Disease control TerminatedX-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder, which affects boys. It is caused by an error in a gene that makes part of the immune system. The basic defect lies in specialised white blood cells called phagocytic cells (or phagocytes), which are respon…
Phase: PHASE1, PHASE2 • Sponsor: Genethon • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New oral drug takes on standard chemo for head and neck cancer
Disease control CompletedThis randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for sarcoma patients: drug slows tumor growth in late-stage trial
Disease control CompletedThis is an international (France, Austria and Germany), randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in patients with histologically proven metastatic and/or unresectable Soft Tissue Sarcoma (STS) after failure or…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Breast cancer study tests best order for chemo and hormone pills
Disease control OngoingBreast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocrine therapy the optimal timing for their has not been clearly defined yet.
Phase: PHASE3 • Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New chemo combo aims to beat standard treatment for tough germ cell tumors
Disease control OngoingThe purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other co…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug could extend life for mesothelioma patients
Disease control OngoingThis is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in…
Phase: PHASE2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Extra measles shot at 4 months may slash child deaths
Prevention CompletedBackground: All observational studies and a few randomised controlled trials (RCT) suggest that early measles vaccine (MV), in particular an early two-dose strategy, has a much better effect on overall mortality than later MV. These results suggest that MV has a non-measles relat…
Phase: PHASE4 • Sponsor: Bandim Health Project • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
New lymphoma treatment aims to boost cure rates and cut radiation risks
Disease control CompletedThe purpose of this study is to compare the outcomes across the 4 different treatment groups. The investigators hope that this treatment will improve the ability to cure more patients with HL and also limit the long-term side effects from the treatment. Although eliminating radia…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could extra chemo drugs boost ewing sarcoma survival?
Disease control OngoingThe purpose of this study is to find out what effects, good and/or bad, the combination of irinotecan and temozolomide has on Ewing sarcoma. Irinotecan and temozolomide are chemotherapy drugs that are used very often to treat pediatric patients at MSKCC. The investigators have u…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Clot-Busting device could change stroke care
Disease control CompletedThe Ischemic Brain Vascular Accident (CVA) is a major public health issue. An Early and appropriate charging anyone with stroke is essential to reduce mortality, reduce dependency and promote recovery of autonomy. Intravenous fibrinolysis in patients with cerebral infarction (NIN…
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New radiation approach shows promise for prostate cancer control
Disease control CompletedThe present study evaluates the safety, feasibility, quality-of-life effects, PSA kinetics, and clinical outcomes of definitive dose-escalated external beam radiotherapy for localized adenocarcinoma of the prostate. Eligible patients will have biopsy-proven localized prostate ad…
Phase: NA • Sponsor: Fundacao Champalimaud • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo may offer fewer side effects for early breast cancer patients
Disease control CompletedThis research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are t…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Milder stem cell transplant shows promise for kids with immune disorders
Disease control OngoingThis study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression i…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingA Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic compl…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
A picture of your arteries could be worth a thousand prescriptions
Disease control OngoingThe purpose of VIPVIZA is to assess the impact of pictorial information about asymptomatic atherosclerotic disease to both physician and patient, for improving physicians' adherence to prevention guidelines and patient perception and understanding of the cardiovascular disease (C…
Phase: NA • Sponsor: Umeå University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could 5 radiation sessions be as good as 26 for prostate cancer?
Disease control OngoingAccelerated Hypofractionation Radiotherapy for prostate cancer of 36.25 Gy delivered in 5 fractions will not be inferior to the standard treatment of 70.2 Gy given in 26 fractions with respect to four-year biochemical failure (PSA failure) by Phoenix definition post-treatment com…
Phase: NA • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New CAR T-Cell combo shows promise for tough lymphoma
Disease control OngoingThe purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Radiation plus drug may boost survival in advanced liver cancer
Disease control CompletedThis randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the …
Phase: PHASE3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC